International Patent: ANTIBODY DIRECTED ENZYME PRO-DRUG THERAPY (ADEPT) FOR CANCER TREATMENT USING AN ANTIBODY OR FRAGMENT THAT BINDS TO A CD206 RECEPTOR AND 3-CYCLOPENTYL-ALPHA-PHENYLALANINE-METHOTREXATE

GENEVA, July 6 -- POINT LOMA NAZARENE UNIVERSITY filed a patent application (US2025/060940) for “ANTIBODY DIRECTED ENZYME PRO-DRUG THERAPY (ADEPT) FOR CANCER TREATMENT USING AN ANTIBODY OR FRAGMENT THAT BINDS TO A CD206 RECEPTOR AND 3-CYCLOPENTYL-ALPHA-PHENYLALANINE-METHOTREXATE”. With publication no. WO/2026/143022, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 47/68

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....